Rodolphe Thiebaut

List of Publications by Year
in descending order

211 papers	14,774 citations	30070 54 h-index	20358 116 g-index
230 all docs	230 docs citations	230 times ranked	15564 citing authors

#	Article	IF	Citations
1	Combination Antiretroviral Therapy and the Risk of Myocardial Infarction. New England Journal of Medicine, 2003, 349, 1993-2003.	27.0	1,560
2	Class of Antiretroviral Drugs and the Risk of Myocardial Infarction. New England Journal of Medicine, 2007, 356, 1723-1735.	27.0	1,393
3	Cardiovascular disease risk factors in HIV patients – association with antiretroviral therapy. Results from the DAD study. Aids, 2003, 17, 1179-1193.	2.2	770
4	Systems analysis of sex differences reveals an immunosuppressive role for testosterone in the response to influenza vaccination. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, 869-874.	7.1	542
5	Effectiveness of prenatal treatment for congenital toxoplasmosis: a meta-analysis of individual patients' data. Lancet, The, 2007, 369, 115-122.	13.7	439
6	Factors associated with specific causes of death amongst HIV-positive individuals in the D:A:D study. Aids, 2010, 24, 1537-1548.	2.2	381
7	SHORT STATEMENT OF THE FIRST EUROPEAN CONSENSUS CONFERENCE ON THE TREATMENT OF CHRONIC HEPATITIS B AND C IN HIV CO-INFECTED PATIENTS. Journal of Hepatology, 2005, 42, 615-624.	3.7	357
8	Effect of transmitted drug resistance on virological and immunological response to initial combination antiretroviral therapy for HIV (EuroCoord-CHAIN joint project): a European multicohort study. Lancet Infectious Diseases, The, 2011, 11, 363-371.	9.1	345
9	Cardiovascular disease risk factors in HIV patients--association with antiretroviral therapy. Results from the DAD study. Aids, 2003, 17, 1179-93.	2.2	335
10	Low-Frequency HIV-1 Drug Resistance Mutations and Risk of NNRTI-Based Antiretroviral Treatment Failure. JAMA - Journal of the American Medical Association, 2011, 305, 1327.	7.4	315
11	Predicting the risk of cardiovascular disease in HIV-infected patients: the Data collection on Adverse Effects of Anti-HIV Drugs Study. European Journal of Cardiovascular Prevention and Rehabilitation, 2010, 17, 491-501.	2.8	309
12	Enhanced T cell recovery in HIV-1–infected adults through IL-7 treatment. Journal of Clinical Investigation, 2009, 119, 997-1007.	8.2	288
13	Prognosis of HIV-1-infected patients up to 5 years after initiation of HAART: collaborative analysis of prospective studies. Aids, 2007, 21, 1185-1197.	2.2	264
14	Prevalence of resistance to nevirapine in mothers and children after single-dose exposure to prevent vertical transmission of HIV-1: a meta-analysis€. International Journal of Epidemiology, 2007, 36, 1009-1021.	1.9	207
15	Effectiveness of disease-management programs for improving diabetes care: a meta-analysis. Cmaj, 2011, 183, E115-E127.	2.0	202
16	Non-AIDS-defining deaths and immunodeficiency in the era of combination antiretroviral therapy. Aids, 2009, 23, 1743-1753.	2.2	200
17	Reduced bone mineral density in HIV-infected patients: prevalence and associated factors. Aids, 2008, 22, 395-402.	2.2	188
18	Universal test and treat and the HIV epidemic in rural South Africa: a phase 4, open-label, community cluster randomised trial. Lancet HIV,the, 2018, 5, e116-e125.	4.7	187

#	Article	IF	Citations
19	Time From Human Immunodeficiency Virus Seroconversion to Reaching CD4+ Cell Count Thresholds <200, <350, and <500 Cells/mm3: Assessment of Need Following Changes in Treatment Guidelines. Clinical Infectious Diseases, 2011, 53, 817-825.	5.8	180
20	Guidelines for reporting methodological challenges and evaluating potential bias in dementia research. Alzheimer's and Dementia, 2015, 11, 1098-1109.	0.8	169
21	Universal Definition of Loss to Follow-Up in HIV Treatment Programs: A Statistical Analysis of 111 Facilities in Africa, Asia, and Latin America. PLoS Medicine, 2011, 8, e1001111.	8.4	167
22	Robustness of the linear mixed model to misspecified error distribution. Computational Statistics and Data Analysis, 2007, 51, 5142-5154.	1.2	162
23	Lipodystrophy, Metabolic Disorders, and Human Immunodeficiency Virus Infection: Aquitaine Cohort, France, 1999. Clinical Infectious Diseases, 2000, 31, 1482-1487.	5.8	152
24	Long-term Mortality in HIV-Positive Individuals Virally Suppressed for >3 Years With Incomplete CD4 Recovery. Clinical Infectious Diseases, 2014, 58, 1312-1321.	5.8	140
25	Uptake of Home-Based HIV Testing, Linkage to Care, and Community Attitudes about ART in Rural KwaZulu-Natal, South Africa: Descriptive Results from the First Phase of the ANRS 12249 TasP Cluster-Randomised Trial. PLoS Medicine, 2016, 13, e1002107.	8.4	135
26	A novel approach for biomarker selection and the integration of repeated measures experiments from two assays. BMC Bioinformatics, 2012, 13, 325.	2.6	129
27	Evaluation of cardiovascular risk factors in HIV-1 infected patients using carotid intima-media thickness measurement. Annals of Medicine, 2002, 34, 55-63.	3.8	118
28	Safety and immunogenicity of a two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen in adults in Europe (EBOVAC2): a randomised, observer-blind, participant-blind, placebo-controlled, phase 2 trial. Lancet Infectious Diseases, The, 2021, 21, 493-506.	9.1	115
29	Predictors of Long‐Term Increase in CD4+Cell Counts in Human Immunodeficiency Virus–Infected Patients Receiving a Protease Inhibitor–Containing Antiretroviral Regimen. Journal of Infectious Diseases, 2002, 185, 471-480.	4.0	114
30	Antiretroviral therapy in pregnant women with advanced HIV disease and pregnancy outcomes in Abidjan, Côte d'Ivoire. Aids, 2008, 22, 1815-1820.	2.2	110
31	Quantifying Thymic Export: Combining Models of Naive T Cell Proliferation and TCR Excision Circle Dynamics Gives an Explicit Measure of Thymic Output. Journal of Immunology, 2009, 183, 4329-4336.	0.8	110
32	Systems Vaccinology Identifies an Early Innate Immune Signature as a Correlate of Antibody Responses to the Ebola Vaccine rVSV-ZEBOV. Cell Reports, 2017, 20, 2251-2261.	6.4	107
33	Decrease in circulating dendritic cells predicts fatal outcome in septic shock. Intensive Care Medicine, 2007, 33, 148-152.	8.2	104
34	Prevention of Ebola virus disease through vaccination: where we are in 2018. Lancet, The, 2018, 392, 787-790.	13.7	103
35	Predictors of Hypertension and Changes of Blood Pressure in HIV-Infected Patients. Antiviral Therapy, 2005, 10, 811-823.	1.0	103
36	Dendritic cell‐based therapeutic vaccine elicits polyfunctional HIV‐specific T‐cell immunity associated with control of viral load. European Journal of Immunology, 2014, 44, 2802-2810.	2.9	102

#	Article	IF	Citations
37	Role of Uncontrolled HIV RNA Level and Immunodeficiency in the Occurrence of Malignancy in HIV-Infected Patients during the Combination Antiretroviral Therapy Era: Agence Nationale de Recherche sur le Sida (ANRS) CO3 Aquitaine Cohort. Clinical Infectious Diseases, 2009, 49, 1109-1116.	5.8	100
38	Mixed models for longitudinal left-censored repeated measures. Computer Methods and Programs in Biomedicine, 2004, 74, 255-260.	4.7	94
39	Bivariate linear mixed models using SAS proc MIXED. Computer Methods and Programs in Biomedicine, 2002, 69, 249-256.	4.7	93
40	Transmission of HIV-1 minority-resistant variants and response to first-line antiretroviral therapy. Aids, 2008, 22, 1417-1423.	2.2	92
41	The Incidence of AIDS-Defining Illnesses at a Current CD4 Count ≥200 Cells/µL in the Post–Combination Antiretroviral Therapy Era. Clinical Infectious Diseases, 2013, 57, 1038-1047.	5.8	92
42	Impact of HIV-1 Subtype on CD4 Count at HIV Seroconversion, Rate of Decline, and Viral Load Set Point in European Seroconverter Cohorts. Clinical Infectious Diseases, 2013, 56, 888-897.	5.8	88
43	Clinical progression of HIV-1 infection according to the viral response during the first year of antiretroviral treatment. Aids, 2000, 14, 971-978.	2.2	80
44	Comparison of viro-immunological marker changes between HIV-1 and HIV-2-infected patients in France. Aids, 2008, 22, 457-468.	2.2	80
45	An Evaluation of HIV Elite Controller Definitions within a Large Seroconverter Cohort Collaboration. PLoS ONE, 2014, 9, e86719.	2.5	80
46	The Role of Mannose-Binding Lectin in Susceptibility to Infection in Preterm Neonates. Pediatric Research, 2008, 63, 680-685.	2.3	78
47	Joint modelling of bivariate longitudinal data with informative dropout and left-censoring, with application to the evolution of CD4+ cell count and HIV RNA viral load in response to treatment of HIV infection. Statistics in Medicine, 2005, 24, 65-82.	1.6	76
48	Evidence that an Identical T Cell Clone in Skin and Peripheral Blood Lymphocytes is an Independent Prognostic Factor in Primary Cutaneous T Cell Lymphomas. Journal of Investigative Dermatology, 2001, 117, 920-926.	0.7	74
49	Predicting Patterns of Long-Term CD4 Reconstitution in HIV-Infected Children Starting Antiretroviral Therapy in Sub-Saharan Africa: A Cohort-Based Modelling Study. PLoS Medicine, 2013, 10, e1001542.	8.4	71
50	Changes over calendar time in the risk of specific first AIDS-defining events following HIV seroconversion, adjusting for competing risks. International Journal of Epidemiology, 2002, 31, 951-958.	1.9	64
51	Prenatal therapy with pyrimethamine + sulfadiazine vs spiramycin to reduce placental transmission of toxoplasmosis: a multicenter, randomized trial. American Journal of Obstetrics and Gynecology, 2018, 219, 386.e1-386.e9.	1.3	64
52	Effect of Cytomegalovirus-Induced Immune Response, Self Antigen–Induced Immune Response, and Microbial Translocation on Chronic Immune Activation in Successfully Treated HIV Type 1–Infected Patients: The ANRS CO3 Aquitaine Cohort. Journal of Infectious Diseases, 2013, 207, 622-627.	4.0	61
53	Time-Course Gene Set Analysis for Longitudinal Gene Expression Data. PLoS Computational Biology, 2015, 11, e1004310.	3.2	60
54	Repeated Cycles of Recombinant Human Interleukin 7 in HIV-Infected Patients With Low CD4 T-Cell Reconstitution on Antiretroviral Therapy: Results of 2 Phase II Multicenter Studies. Clinical Infectious Diseases, 2016, 62, 1178-1185.	5.8	59

#	Article	IF	Citations
55	Factors Associated with the Occurrence of AIDS-Related Non-Hodgkin Lymphoma in the Era of Highly Active Antiretroviral Therapy: Aquitaine Cohort, France. Clinical Infectious Diseases, 2006, 42, 411-417.	5.8	58
56	Prediction of Cytomegalovirus (CMV) Plasma Load from Evaluation of CMV Whole-Blood Load in Samples from Renal Transplant Recipients. Journal of Clinical Microbiology, 2008, 46, 493-498.	3.9	56
57	Occurrence of Listeria spp. in Effluents of French Urban Wastewater Treatment Plants. Applied and Environmental Microbiology, 2005, 71, 7562-7566.	3.1	55
58	Low CD4/CD8 Ratio Is Associated with Non AIDS-Defining Cancers in Patients on Antiretroviral Therapy: ANRS CO8 (Aproco/Copilote) Prospective Cohort Study. PLoS ONE, 2016, 11, e0161594.	2.5	55
59	Bone Marrow Histopathologic and Molecular Staging in Epidermotropic T-Cell Lymphomas. American Journal of Clinical Pathology, 2003, 119, 414-423.	0.7	51
60	Group and sparse group partial least square approaches applied in genomics context. Bioinformatics, 2016, 32, 35-42.	4.1	50
61	Immune Alterations in a Patient with SARS-CoV-2-Related Acute Respiratory Distress Syndrome. Journal of Clinical Immunology, 2020, 40, 1082-1092.	3.8	48
62	Association of immune-activation and senescence markers with non-AIDS-defining comorbidities in HIV-suppressed patients. Aids, 2015, 29, 2099-2108.	2.2	47
63	Random forests for high-dimensional longitudinal data. Statistical Methods in Medical Research, 2021, 30, 166-184.	1.5	44
64	Weight Loss and Body Mass Index as Predictors of HIV Disease Progression to AIDS in Adults. Aquitaine Cohort, France, 1985â€"1997. Journal of the American College of Nutrition, 2001, 20, 609-615.	1.8	43
65	Predictors of hypertension and changes of blood pressure in HIV-infected patients. Antiviral Therapy, 2005, 10, 811-23.	1.0	43
66	Surveillance of Î³Î´ T Cells Predicts Cytomegalovirus Infection Resolution in Kidney Transplants. Journal of the American Society of Nephrology: JASN, 2016, 27, 637-645.	6.1	41
67	Innate gene signature distinguishes humoral versus cytotoxic responses to influenza vaccination. Journal of Clinical Investigation, 2019, 129, 1960-1971.	8.2	41
68	Estimation of dynamical model parameters taking into account undetectable marker values. BMC Medical Research Methodology, 2006, 6, 38.	3.1	40
69	Long-term nonprogressors and elite controllers in the ANRS CO5 HIV-2 cohort. Aids, 2011, 25, 865-867.	2.2	38
70	Effects of a physical activity programme to prevent physical performance decline in oncoâ€geriatric patients: a randomized multicentre trial. Journal of Cachexia, Sarcopenia and Muscle, 2019, 10, 287-297.	7.3	38
71	Immunological markers after long-term treatment interruption in chronically HIV-1 infected patients with CD4 cell count above 400 Ã— 106 cells/l. Aids, 2005, 19, 53-61.	2.2	36
72	Effect of age on immunological response in the first year of antiretroviral therapy in HIV-1-infected adults in West Africa. Aids, 2012, 26, 951-957.	2.2	36

#	Article	IF	Citations
73	Clonally Diverse T Cell Homeostasis Is Maintained by a Common Program of Cell-Cycle Control. Journal of Immunology, 2013, 190, 3985-3993.	0.8	35
74	Change in atherosclerosis progression in HIV-infected patients: ANRS Aquitaine Cohort, 1999â€"2004. Aids, 2005, 19, 729-731.	2.2	34
75	Heterogeneity in outcomes of treated HIV-positive patients in Europe and North America: relation with patient and cohort characteristics. International Journal of Epidemiology, 2012, 41, 1807-1820.	1.9	34
76	The impact of population dynamics on the population <scp>HIV</scp> care cascade: results from the <scp>ANRS</scp> 12249 Treatment as Prevention trial in rural KwaZuluâ€Natal (South Africa). Journal of the International AIDS Society, 2018, 21, e25128.	3.0	34
77	Safety and immunogenicity of 2-dose heterologous Ad26.ZEBOV, MVA-BN-Filo Ebola vaccination in healthy and HIV-infected adults: A randomised, placebo-controlled Phase II clinical trial in Africa. PLoS Medicine, 2021, 18, e1003813.	8.4	34
78	Presence of the Metabolic Syndrome Is Not a Better Predictor of Cardiovascular Disease Than the Sum of Its Components in HIV-Infected Individuals: Data Collection on Adverse events of Anti-HIV Drugs (D:A:D) study. Diabetes Care, 2009, 32, 474-480.	8.6	33
79	Virological and immunological response in HIV-1-infected patients with multiple treatment failures receiving raltegravir and optimized background therapy, ANRS CO3 Aquitaine Cohort. Journal of Antimicrobial Chemotherapy, 2009, 63, 1251-1255.	3.0	33
80	Methodological issues in the use of composite endpoints in clinical trials: examples from the HIV field. Clinical Trials, 2010, 7, 19-35.	1.6	33
81	Risk factors for colonization and infection by Pseudomonas aeruginosa in patients hospitalized in intensive care units in France. PLoS ONE, 2018, 13, e0193300.	2.5	33
82	Long-lasting severe immune dysfunction in Ebola virus disease survivors. Nature Communications, 2020, 11, 3730.	12.8	33
83	Temporal trends in prognostic markers of HIV-1 virulence and transmissibility: an observational cohort study. Lancet HIV,the, 2014, 1, e119-e126.	4.7	32
84	Characteristics of HIV-2 and HIV-1/HIV-2 Dually Seropositive Adults in West Africa Presenting for Care and Antiretroviral Therapy: The IeDEA-West Africa HIV-2 Cohort Study. PLoS ONE, 2013, 8, e66135.	2.5	32
85	First-year lymphocyte T CD4+ response to antiretroviral therapy according to the HIV type in the IeDEA West Africa collaboration. Aids, 2010, 24, 1043-1050.	2.2	31
86	Health Care Studentsâ€™ Knowledge of and Attitudes, Beliefs, and Practices Toward the French COVID-19 App: Cross-sectional Questionnaire Study. Journal of Medical Internet Research, 2021, 23, e26399.	4.3	31
87	Efavirenz-associated breast hypertrophy in HIV-infected patients. Aids, 2001, 15, 126-129.	2.2	30
88	Development of a fixed module repertoire for the analysis and interpretation of blood transcriptome data. Nature Communications, 2021, 12, 4385.	12.8	29
89	Reliable assessment of the incidence of childhood autoimmune hemolytic anemia. Pediatric Blood and Cancer, 2017, 64, e26683.	1.5	27
90	Difference in Absolute CD4+ Count According to CD4 Percentage between Asian and Caucasian HIV-Infected Patients. Journal of AIDS & Clinical Research, 2010, 01, 1-4.	0.5	27

#	Article	IF	Citations
91	Safety and immunogenicity of 2-dose heterologous Ad26.ZEBOV, MVA-BN-Filo Ebola vaccination in children and adolescents in Africa: A randomised, placebo-controlled, multicentre Phase II clinical trial. PLoS Medicine, 2022, 19, e1003865.	8.4	27
92	Biases in observational studies of the effect of prenatal treatment for congenital toxoplasmosis. European Journal of Obstetrics, Gynecology and Reproductive Biology, 2006, 124, 3-9.	1.1	26
93	Interpretation of Genotype and Pharmacokinetics for Resistance to Fosamprenavir-Ritonavir-Based Regimens in Antiretroviral-Experienced Patients. Antimicrobial Agents and Chemotherapy, 2007, 51, 1473-1480.	3.2	26
94	Dose‑finding design using mixed‑effect proportional odds model for longitudinal graded toxicity data in phase I oncology clinical trials. Statistics in Medicine, 2013, 32, 5430-5447.	1.6	26
95	Dynamics of the Humoral Immune Response to a Prime-Boost Ebola Vaccine: Quantification and Sources of Variation. Journal of Virology, 2019, 93, .	3.4	26
96	Virological Response to Darunavir/Ritonavir-Based Regimens in Antiretroviral-Experienced Patients (PREDIZISTA Study). Antiviral Therapy, 2008, 13, 271-280.	1.0	25
97	Pediatric Human Immunodeficiency Virus Infection and Circulating IgD+ Memory B Cells. Journal of Infectious Diseases, 2008, 198, 481-485.	4.0	24
98	Association of Soluble CD14 and Inflammatory Biomarkers With HIV-2 Disease Progression. Clinical Infectious Diseases, 2012, 55, 1417-1425.	5.8	24
99	HIV Controllers Have Low Inflammation Associated with a Strong HIV-Specific Immune Response in Blood. Journal of Virology, 2019, 93, .	3.4	24
100	Determinants of Restoration of CD4 and CD8 Cell Counts and Their Ratio in HIV-1–Positive Individuals With Sustained Virological Suppression on Antiretroviral Therapy. Journal of Acquired Immune Deficiency Syndromes (1999), 2019, 80, 292-300.	2.1	24
101	Primary Resistance to Enfuvirtide (T20) in recently HIV-1 Infected, Antiretroviral-Naive Patients from the ANRS Aquitaine Cohort. Antiviral Therapy, 2007, 12, 559-562.	1.0	24
102	Quantification of the Relative Importance of CTL, B Cell, NK Cell, and Target Cell Limitation in the Control of Primary SIV-Infection. PLoS Computational Biology, 2011, 7, e1001103.	3.2	23
103	Decreased HIV-Specific T-Regulatory Responses Are Associated with Effective DC-Vaccine Induced Immunity. PLoS Pathogens, 2015, 11, e1004752.	4.7	23
104	Diabetes and cognitive decline in a French cohort of patients infected with HIV-1. Neurology, 2015, 85, 1065-1073.	1.1	23
105	Pravastatin in HIV-Infected Patients Treated with Protease Inhibitors: A Placebo-Controlled Randomized Study. HIV Clinical Trials, 2007, 8, 53-60.	2.0	22
106	Evolution of 2-long terminal repeat (2-LTR) episomal HIV-1 DNA in raltegravir-treated patients and in in vitro infected cells. Journal of Antimicrobial Chemotherapy, 2010, 65, 434-437.	3.0	22
107	Targeting SARS-CoV-2 receptor-binding domain to cells expressing CD40 improves protection to infection in convalescent macaques. Nature Communications, 2021, 12, 5215.	12.8	22
108	mTOR Inhibitors Prevent CMV Infection through the Restoration of Functional $\alpha\beta$ and $\gamma\delta$ T cells in Kidney Transplantation. Journal of the American Society of Nephrology: JASN, 2022, 33, 121-137.	6.1	22

#	Article	IF	Citations
109	cytometree: A binary tree algorithm for automatic gating in cytometry analysis. Cytometry Part A: the Journal of the International Society for Analytical Cytology, 2018, 93, 1132-1140.	1.5	21
110	Ebola vaccine development: Systematic review of pre-clinical and clinical studies, and meta-analysis of determinants of antibody response variability after vaccination. International Journal of Infectious Diseases, 2018, 74, 83-96.	3.3	21
111	Effect of intermittent interleukin-2 therapy on CD4+ T-cell counts following antiretroviral cessation in patients with HIV. Aids, 2012, 26, 711-720.	2.2	20
112	Treatment Monitoring of HIVâ€‑Infected Patients based on Mechanistic Models. Biometrics, 2012, 68, 902-911.	1.4	20
113	Quantifying and Predicting the Effect of Exogenous Interleukin-7 on CD4+T Cells in HIV-1 Infection. PLoS Computational Biology, 2014, 10, e1003630.	3.2	20
114	Kaposi Sarcoma Risk in HIV-Infected Children and Adolescents on Combination Antiretroviral Therapy From Sub-Saharan Africa, Europe, and Asia. Clinical Infectious Diseases, 2016, 63, ciw519.	5.8	20
115	Targeting HIV-1 Env gp140 to LOX-1 Elicits Immune Responses in Rhesus Macaques. PLoS ONE, 2016, 11, e0153484.	2.5	20
116	Preservation of Lymphopoietic Potential and Virus Suppressive Capacity by CD8+ T Cells in HIV-2â€"Infected Controllers. Journal of Immunology, 2016, 197, 2787-2795.	0.8	19
117	Viral rebound in semen after antiretroviral treatment interruption in an HIV therapeutic vaccine double-blind trial. Aids, 2019, 33, 279-284.	2.2	19
118	Time-Updated CD4+ T Lymphocyte Count and HIV RNA as Major Markers of Disease Progression in Naive HIV-1-Infected Patients Treated With a Highly Active Antiretroviral Therapy. Journal of Acquired Immune Deficiency Syndromes (1999), 2003, 33, 380-386.	2.1	18
119	Behavioral audiometry: protocols for measuring hearing thresholds in babies aged 4â€"18 months. International Journal of Pediatric Otorhinolaryngology, 2004, 68, 1233-1243.	1.0	18
120	NIMROD: A program for inference via a normal approximation of the posterior in models with random effects based on ordinary differential equations. Computer Methods and Programs in Biomedicine, 2013, 111, 447-458.	4.7	18
121	dearseq: a variance component score test for RNA-seq differential analysis that effectively controls the false discovery rate. NAR Genomics and Bioinformatics, 2020, 2, lqaa093.	3.2	18
122	Heterogeneous viral environment in a HIV spatial model. Discrete and Continuous Dynamical Systems - Series B, 2011, 15, 545-572.	0.9	18
123	Bivariate Longitudinal Model For The Analysis Of The Evolution Of Hiv Rna And Cd4 Cell Count In Hiv Infection Taking Into Account Left Censoring Of Hiv Rna Measures. Journal of Biopharmaceutical Statistics, 2003, 13, 271-282.	0.8	17
124	CD4 cell count response to first-line combination ART in HIV-2+ patients compared with HIV-1+ patients: a multinational, multicohort European study. Journal of Antimicrobial Chemotherapy, 2017, 72, 2869-2878.	3.0	17
125	Can highly active antiretroviral therapy be interrupted in patients with sustained moderate HIV RNA and > 400 CD4+ cells/Âµl? Impact on immunovirological parameters. Journal of Medical Virology, 2005, 77, 164-172.	5.0	16
126	Cytokine and gene transcription profiles of immune responses elicited by HIV lipopeptide vaccine in HIV-negative volunteers. Aids, 2013, 27, 1421-1431.	2.2	16

#	Article	IF	Citations
127	Atherogen lipid profile in HIV-1-infected patients with lipodystrophy syndrome. European Journal of Internal Medicine, 2000, 11, 257-263.	2.2	15
128	A multistate approach for estimating the incidence of human immunodeficiency virus by using data from a prevalent cohort study. Journal of the Royal Statistical Society Series C: Applied Statistics, 2005, 54, 739-752.	1.0	15
129	Initiation of c-ART in HIV-1 Infected Patients Is Associated With a Decrease of the Metabolic Activity of the Thymus Evaluated Using FDG-PET/Computed Tomography. Journal of Acquired Immune Deficiency Syndromes (1999), 2012, 61, 56-63.	2.1	15
130	Reproducibility issues in science, is <i>P</i> value really the only answer?. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, E1934.	7.1	14
131	Sequential Dirichlet process mixtures of multivariate skew t-distributions for model-based clustering of flow cytometry data. Annals of Applied Statistics, 2019, 13, .	1.1	14
132	Dose finding with longitudinal data: simpler models, richer outcomes. Statistics in Medicine, 2015, 34, 2983-2998.	1.6	13
133	Immunologic response in treatmentâ€naÃ¯ve HIVâ€2â€infected patients: the IeDEA West Africa cohort. Journal of the International AIDS Society, 2016, 19, 20044.	3.0	13
134	A model for establishment, maintenance and reactivation of the immune response after vaccination against Ebola virus. Journal of Theoretical Biology, 2020, 495, 110254.	1.7	13
135	Superior Efficacy of a Human Immunodeficiency Virus Vaccine Combined with Antiretroviral Prevention in Simian-Human Immunodeficiency Virus-Challenged Nonhuman Primates. Journal of Virology, 2016, 90, 5315-5328.	3.4	12
136	B7-H6-mediated downregulation of NKp30 in natural killer cells contributes to HIV-2 immune escape. Aids, 2019, 33, 23-32.	2.2	12
137	Virologic and Immunologic Response to cART by HIV-1 Subtype in the CASCADE Collaboration. PLoS ONE, 2013, 8, e71174.	2.5	12
138	Treatment of dyslipidaemia in HIV-infected persons. Expert Opinion on Pharmacotherapy, 2005, 6, 1619-1645.	1.8	11
139	Behavioral audiometry: Validity of audiometric measurements obtained using the â€œDelaroche protocolâ€•in babies aged 4â€"18 months suffering from bilateral sensorineural hearing loss. International Journal of Pediatric Otorhinolaryngology, 2006, 70, 993-1002.	1.0	11
140	A new endpoint definition improved clinical relevance and statistical power in a vaccine trial. Journal of Clinical Epidemiology, 2009, 62, 1054-1061.	5.0	11
141	Accelerating clinical development of HIV vaccine strategies: methodological challenges and considerations in constructing an optimised multi-arm phase I/II trial design. Trials, 2014, 15, 68.	1.6	11
142	HIV-1 T cell epitopes targeted to Rhesus macaque CD40 and DCIR: A comparative study of prototype dendritic cell targeting therapeutic vaccine candidates. PLoS ONE, 2018, 13, e0207794.	2.5	11
143	Microbial Translocation Does Not Drive Immune Activation in Ugandan Children Infected With HIV. Journal of Infectious Diseases, 2019, 219, 89-100.	4.0	11
144	Gene Expression Signatures Associated With Immune and Virological Responses to Therapeutic Vaccination With Dendritic Cells in HIV-Infected Individuals. Frontiers in Immunology, 2019, 10, 874.	4.8	11

#	Article	IF	Citations
145	Immunological Monitoring of Calcineurin Inhibitors for Predicting Cytomegalovirus Infection in Kidney Transplant Recipients. Transplantation, 2008, 86, 1060-1067.	1.0	10
146	Comparison of Early CD4 T-Cell Count in HIV-1 Seroconverters in CÃ´te d'Ivoire and France: The ANRS PRIMO-CI and SEROCO Cohorts. Journal of Acquired Immune Deficiency Syndromes (1999), 2010, 53, 260-265.	2.1	10
147	CD4+ T cell recovery during suppression of HIV replication: an international comparison of the immunological efficacy of antiretroviral therapy in North America, Asia and Africa. International Journal of Epidemiology, 2015, 44, 251-263.	1.9	10
148	Optimization and evaluation of Luminex performance with supernatants of antigen-stimulated peripheral blood mononuclear cells. BMC Immunology, 2016, 17, 44.	2.2	10
149	Design, immunogenicity, and efficacy of a pan-sarbecovirus dendritic-cell targeting vaccine. EBioMedicine, 2022, 80, 104062.	6.1	10
150	Options for clinical trials of pre and post-natal treatments for congenital toxoplasmosis. Memorias Do Instituto Oswaldo Cruz, 2009, 104, 299-304.	1.6	9
151	Joint Modeling of the Clinical Progression and of the Biomarkers' Dynamics Using a Mechanistic Model. Biometrics, 2011, 67, 59-66.	1.4	9
152	Sparse partial least squares with group and subgroup structure. Statistics in Medicine, 2018, 37, 3338-3356.	1.6	9
153	Change in T-Lymphocyte Count after Initiation of Highly Active Antiretroviral Therapy in HIV-Infected Patients with History of <i>Mycobacterium Avium</i> Complex Infection. Antiviral Therapy, 2006, 11, 343-350.	1.0	9
154	Ribavirin Plasma Concentration Predicts Sustained Virological Response to Peginterferon Alfa 2a Plus Ribavirin in Previously Treated HCV-HIVâ€"Coinfected Patients. Journal of Acquired Immune Deficiency Syndromes (1999), 2009, 52, 428-430.	2.1	8
155	Maximum a Posteriori Estimation in Dynamical Models of Primary HIV Infection. Statistical Communications in Infectious Diseases, 2012, 4, .	0.2	8
156	Dynamic Models for Estimating the Effect of HAART on CD4 in Observational Studies: Application to the Aquitaine Cohort and the Swiss HIV Cohort Study. Biometrics, 2017, 73, 294-304.	1.4	8
157	Limited HIV-2 reservoirs in central-memory CD4 T-cells associated to CXCR6 co-receptor expression in attenuated HIV-2 infection. PLoS Pathogens, 2019, 15, e1007758.	4.7	8
158	No Positive Association between Vitamin D Level and Immune Responses to Hepatitis B and Streptococcus pneumoniae Vaccination in HIV-Infected Adults. PLoS ONE, 2016, 11, e0168640.	2.5	8
159	T Cell Immunogenicity, Gene Expression Profile, and Safety of Four Heterologous Prime-Boost Combinations of HIV Vaccine Candidates in Healthy Volunteers: Results of the Randomized Multi-Arm Phase I/II ANRS VRI01 Trial. Journal of Immunology, 2022, 208, 2663-2674.	0.8	8
160	Score Tests for Exploring Complex Models: Application to HIV Dynamics Models. Biometrical Journal, 2010, 52, 10-21.	1.0	7
161	Mean CD4 cell count changes in patients failing a first-line antiretroviral therapy in resource-limited settings. BMC Infectious Diseases, 2012, 12, 147.	2.9	7
162	Predictors of CD4+ T-Cell Counts of HIV Type 1â€"Infected Persons After Virologic Failure of All 3 Original Antiretroviral Drug Classes. Journal of Infectious Diseases, 2013, 207, 759-767.	4.0	7

#	Article	IF	Citations
163	Recent developments in clinical trial designs for HIV vaccine research. Human Vaccines and Immunotherapeutics, 2015, 11, 1022-1029.	3.3	7
164	Modeling $\mathrm{CD4}^{+}$ T cells dynamics in HIV-infected patients receiving repeated cycles of exogenous Interleukin 7. Annals of Applied Statistics, 2017, 11, .	1.1	7
165	Visualizing omics and clinical data: Which challenges for dealing with their variety?. Methods, 2018, 132, 3-18.	3.8	7
166	Temporal trends of population viral suppression in the context of Universal Test and Treat: the ANRS 12249 TasP trial in rural South Africa. Journal of the International AIDS Society, 2019, 22, e25402.	3.0	7
167	Modelling the response to vaccine in non-human primates to define SARS-CoV-2 mechanistic correlates of protection. ELife, 0, 11, .	6.0	7
168	Virological response to HIV-1 nucleoside/nucleotide reverse transcriptase inhibitors-based, tenofovir DF-including regimens in the ANRS Aquitaine Cohort. Journal of Clinical Virology, 2006, 36, 95-99.	3.1	6
169	T-cell activation discriminates subclasses of symptomatic primary humoral immunodeficiency diseases in adults. BMC Immunology, 2014, 15, 13.	2.2	6
170	The Impact of the 2013 WHO Antiretroviral Therapy Guidelines on the Feasibility of HIV Population Prevention Trials. HIV Clinical Trials, 2014, 15, 185-198.	2.0	6
171	A method to estimate the size and characteristics of HIV-positive populations using an individual-based stochastic simulation model. Epidemiology, 2015, 27, 1.	2.7	6
172	Lasso regularization for left-censored Gaussian outcome and high-dimensional predictors. BMC Medical Research Methodology, 2018, 18, 159.	3.1	6
173	Barrier Gesture Relaxation during Vaccination Campaign in France: Modelling Impact of Waning Immunity. Covid, 2021, 1, 472-488.	1.5	6
174	Within-host models of SARS-CoV-2: What can it teach us on the biological factors driving virus pathogenesis and transmission?. Anaesthesia, Critical Care & Pain Medicine, 2022, 41, 101055.	1.4	6
175	Mathematical modelling of HIV prevention intervention. Aids, 2013, 27, 475-476.	2.2	5
176	Integrative Analysis of Immunological Data to Explore Chronic Immune T-Cell Activation in Successfully Treated HIV Patients. PLoS ONE, 2017, 12, e0169164.	2.5	5
177	CD4 T cell decline following HIV seroconversion in individuals with and without CXCR4-tropic virus. Journal of Antimicrobial Chemotherapy, 2017, 72, 2862-2868.	3.0	5
178	Controlling IL-7 Injections in HIV-Infected Patients. Bulletin of Mathematical Biology, 2018, 80, 2349-2377.	1.9	5
179	Multi-arm, multi-stage randomised controlled trials for evaluating therapeutic HIV cure interventions. Lancet HIV,the, 2019, 6, e334-e340.	4.7	5
180	Evolution of body composition following successful kidney transplantation is strongly influenced by physical activity: results of the CORPOS study. BMC Nephrology, 2021, 22, 31.	1.8	5

#	Article	IF	Citations
181	Alternative methods to analyse the impact of HIV mutations on virological response to antiviral therapy. BMC Medical Research Methodology, 2008, 8, 68.	3.1	4
182	On the validity of meta-analyses: exhaustivity must be warranted, exclusion of duplicate patients too. Journal of Clinical Epidemiology, 2010, 63, 342-343.	5.0	4
183	Body composition in 98 patients awaiting kidney transplantation. Nutrition, 2014, 30, 186-191.	2.4	4
184	Improved darunavir genotypic mutation score predicting treatment response for patients infected with HIV-1 subtype B and non-subtype B receiving a salvage regimen. Journal of Antimicrobial Chemotherapy, 2016, 71, 1352-1360.	3.0	4
185	Serum suppression of tumorigenicity 2 level is an independent predictor of all-cause mortality in HIV-infected patients. Aids, 2017, 31, 2355-2365.	2.2	4
186	No compensatory lung growth after resection in a one-year follow-up cohort of patients with lung cancer. Journal of Thoracic Disease, 2017, 9, 3938-3945.	1.4	4
187	Early CD4+ T Cell Responses Are Associated with Subsequent CD8+ T Cell Responses to an rAd5-Based Prophylactic Prime-Boost HIV Vaccine Strategy. PLoS ONE, 2016, 11, e0152952.	2.5	4
188	Change in T-lymphocyte count after initiation of highly active antiretroviral therapy in HIV-infected patients with history of Mycobacterium avium complex infection. Antiviral Therapy, 2006, 11, 343-50.	1.0	4
189	A new method for evaluating the impacts of semantic similarity measures on the annotation of gene sets. PLoS ONE, 2018, 13, e0208037.	2.5	3
190	Adaptive protocols based on predictions from a mechanistic model of the effect of IL7 on CD4 counts. Statistics in Medicine, 2019, 38, 221-235.	1.6	3
191	A Comparison of Cell Activation, Exhaustion, and Expression of HIV Coreceptors and Restriction Factors in HIV-1- and HIV-2-Infected Nonprogressors. AIDS Research and Human Retroviruses, 2021, 37, 214-223.	1.1	3
192	Reconnaître la spécificité de la recherche en santé publique pour améliorer son impact scientifique, sanitaire et sociétal. Sante Publique, 2013, Vol. 24, 383-385.	0.1	3
193	Methodological guidelines to estimate population-based health indicators using linked data and/or machine learning techniques. Archives of Public Health, 2022, 80, 9.	2.4	3
194	CD4 Natural History and Informative Censoring in Sub-Saharan Africa. Journal of Acquired Immune Deficiency Syndromes (1999), 2006, 43, 380-381.	2.1	2
195	Methodological issues of non-inferiority trials in HIV-infected patients: a need for consensus?. Aids, 2008, 22, 996-997.	2.2	2
196	Is the current use of 'positivity' thresholds meaningful for evaluating HIV-vaccine immunogenicity endpoints?. Aids, 2013, 27, 1362-1365.	2.2	2
197	Analyzing cellular immunogenicity in vaccine clinical trials: a new statistical method including non-specific responses for accurate estimation of vaccine effect. Journal of Immunological Methods, 2020, 477, 112711.	1.4	2
198	Conventional Dendritic Cells and Slan+ Monocytes During HIV-2 Infection. Frontiers in Immunology, 2020, 11, 1658.	4.8	2

#	Article	IF	Citations
199	Data‐driven sparse partial least squares. Statistical Analysis and Data Mining, 0, , .	2.8	2
200	Analysis of Undetectable HIV RNA Using Survival Analysis: Results Must Be Interpreted Carefully. HIV Clinical Trials, 2003, 4, 417-420.	2.0	1
201	Vaccines for Therapeutic Cellular Immunity that Target HIV Gag, Pol and Nef Epitopes to CD40 and DCIR Elicit T-cell Responses in Rhesus Macaques. AIDS Research and Human Retroviruses, 2014, 30, A245-A245.	1.1	1
202	New insights are game-changers in HIV-2 disease management. Lancet HIV,the, 2019, 6, e214.	4.7	1
203	NK Cell Subset Redistribution and Antibody Dependent Activation after Ebola Vaccination in Africans. Vaccines, 2022, 10, 884.	4.4	1
204	CMV plasma DNAemia and risk of cancer among HIV-infected patients: A case–control study nested in the ANRS CO3 Aquitaine Cohort, France, 2002–2007. Journal of Clinical Virology, 2011, 50, 177-180.	3.1	0
205	Discussion on the effect of age on immunological response in the first year of antiretroviral therapy in HIV-1-infected adults. Aids, 2013, 27, 146-147.	2.2	0
206	Microbicide-vaccine Combination Provides Significant Protection against Vaginal SHIV-162P3 Challenge in Cynomolgous Monkeys. AIDS Research and Human Retroviruses, 2014, 30, A26-A26.	1.1	0
207	Reply to Bordoni et al. Clinical Infectious Diseases, 2016, 63, 1684-1685.	5.8	0
208	Between-group comparison of area under the curve in clinical trials with censored follow-up: Application to HIV therapeutic vaccines. Statistical Methods in Medical Research, 2021, 30, 2130-2147.	1.5	0
209	Parameters identification for a model of T cell homeostasis. Mathematical Biosciences and Engineering, 2015, 12, 917-936.	1.9	0
210	Bone Marrow Histopathologic and Molecular Staging in Epidermotropic T-Cell Lymphomas. American Journal of Clinical Pathology, 2003, 119, 0-0.	0.7	0
211	Doubly robust evaluation of high-dimensional surrogate markers. Biostatistics, 2023, 24, 985-999.	1.5	0